Biorithm

Biorithm is a Singapore-based health care startup founded in 2015 with a clear mission encapsulated in its slogan, "From the first 9 months to the next 90 years, we treasure every beat." The company aims to revolutionize maternity care by leveraging predictive and precision medicine to eradicate preventable pregnancy complications and stillbirth. Their innovative approach involves the development of cutting-edge analytic software and medical-grade wearables for comprehensive pregnancy data monitoring.

Having recently secured a noteworthy $3.50M Series A investment on 18 December 2023, Biorithm has captured the attention of prominent investors such as SEEDS Capital and Adaptive Capital Partners. By successfully combining medical expertise and engineering excellence, the company has emerged as a frontrunner in women's health and pregnancy care. Additionally, as a spin-off from Nanyang Technological University Singapore (NTU), Biorithm benefits from a strong academic foundation, reinforcing its credibility and potential for long-term success.

Through its commitment to pioneering a new standard in maternity care, Biorithm holds significant promise in improving global pregnancy outcomes, making it an attractive prospect for potential investors seeking impactful and innovative opportunities in the health care sector.